Refine
Has Fulltext
- yes (10)
Is part of the Bibliography
- yes (10)
Document Type
- Journal article (10)
Language
- English (10)
Keywords
- Fabry disease (4)
- depression (2)
- neuropathic pain (2)
- pain (2)
- B7-H1 (1)
- CRPS (1)
- Fabry-associated pain (1)
- MMP9 (1)
- PD-L1 (1)
- RECK (1)
- SNI (1)
- alpha-galactosidase A (1)
- antagomir (1)
- biomarker (1)
- biopsy (1)
- blood nerve barrier (1)
- chronic pain (1)
- claudin-1 (1)
- cognitive impairment (1)
- cortical activation (1)
- enzyme replacement therapy (1)
- expression (1)
- fibromyalgia syndrome (1)
- genetics (1)
- immune system (1)
- immunofluorescence (1)
- inflammatory pain (1)
- inhibition (1)
- involvement (1)
- learning (1)
- mechanisms (1)
- miR-21 (1)
- miRNA (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- microRNA (1)
- mouse model (1)
- mouse models (1)
- near-infrared spectroscopy (1)
- nerve fibers (1)
- nerve ultrasonography (1)
- neuropathy (1)
- pain questionnaire (1)
- peripheral nerve injury (1)
- peripheral neuropathy (1)
- polymorphism (1)
- rat (1)
- receptors (1)
- renal system (1)
- sciatic nerve (1)
- sensory neurons (1)
- skin diseases (1)
- superficial peroneal nerve (1)
- sural nerve (1)
- swimming (1)
- vasculitis (1)
Institute
- Neurologische Klinik und Poliklinik (8)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (2)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Klinische Neurobiologie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurochirurgische Klinik und Poliklinik (1)
EU-Project number / Contract (GA) number
- 602133 (10) (remove)
Background
The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity.
Methods
At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data.
Results
We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy.
Conclusions
Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.